FES-PET could save $142M in breast cancer costs
AuntMinnie
MAY 20, 2024
Adding F-18 fluroestradiol (FES)-PET/CT imaging to standard of care tests in women with suspected estrogen receptor (ER)-positive breast cancer could save the U.S. millions in healthcare costs, according to a study published May 14 in PLOS One. In a budget impact study, GE HealthCare scientists estimated the approach could save up to $142 million over a five-year period, primarily by increasing true-positive and true-negative test results and reducing the need for biopsies, noted a team led by R
Let's personalize your content